Close Menu

BARCELONA – Researchers at the annual meeting of the European Society for Medical Oncology in Barcelona on Saturday presented new results from two trials that indicated advanced non-small cell lung cancer (NSCLC) patients would benefit from treatment with a combination of nivolumab and ipilimumab (Bristol-Myers Squibb's Opdivo and Yervoy), or the third-generation EGFR-tyrosine kinase inhibitor osimertinib (AstraZeneca's Tagrisso).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.